Figure 3.
![Figure 3. Decitabine increased megakaryocyte and erythroid commitment and decreased myeloid commitment. (A) Change in platelet counts with treatment, all patients. (B) Change in absolute neutrophil counts with treatment, all patients. (C) Inverse relationship between platelet and neutrophil counts illustrated by data from UPN 2 (the only patient to sustain grade 4 neutropenia; absolute neutrophil count [ANC] less than 0.5 × 109/L).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/102/12/10.1182_blood-2003-05-1738/6/h82335317003.jpeg?Expires=1722369360&Signature=zW0ILgIL4ERvH2EMSro61e~SXY1ahmjOIDyMRtB0TWiOPbNeYwbt7EcpB1bprGRo8gv05qUiywjgl6fEiS0EdC0sU~YvteO2Oq4uDPg9pIV7KBlGGzzMMdsArd6X-KLoEjffUHnSmpQrQOuQ4ixtJ9qSXftUy8W4th-Pg8ERz5mnNqMnbiu9qKqbMn0VZ0YAWtLTkUALf8JHmrfXsIBIEDilRHpo6jXFhulStpHEXrluO2A5zNx7pn5a9t5aQ14Y4S5ZuW5~VrOl4LxLA2X52CTN4YssEzoB2XKFBYaA9t-yiRmGD52tNCAv2Pp39sGOQI1yVnxddTtOa~CrHHzR8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Decitabine increased megakaryocyte and erythroid commitment and decreased myeloid commitment. (A) Change in platelet counts with treatment, all patients. (B) Change in absolute neutrophil counts with treatment, all patients. (C) Inverse relationship between platelet and neutrophil counts illustrated by data from UPN 2 (the only patient to sustain grade 4 neutropenia; absolute neutrophil count [ANC] less than 0.5 × 109/L).
